DIMERIX LIMITED — Director's Dealing 2013

Mar 11, 2013

==> picture [234 x 87] intentionally omitted <==

12 March 2013

Manager Companies Companies Announcement Office ASX Limited 20 Bridge Street SYDNEY NSW 2000

Dear Sir

Sun Biomedical Limited – Appendix 3Y

We enclose a copy of Appendix 3Y – Change of Director’s Interest Notice for Mr Evan Cross.

We note that this notice is being lodged outside of the prescribed date of lodgement. The late lodgement of the Appendix 3Y was as a result of an administrative oversight by the former Company Secretary and not the Director’s failure to notify the Company of the change of holding in the Company’s securities.

The Company reaffirms that the Directors of the Company have agreed to be bound by the policy for trading in the Company’s securities as referred to in the Company’s Corporate Governance Statement and, in particular, its Securities Trading Policy.

The Company is of the view that the arrangements regarding trading in the Company’s securities are sufficient to ensure that the market is notified within the time frame set out in ASX Listing Rule 3.19A.2.

Yours faithfully

==> picture [85 x 55] intentionally omitted <==

Peter Webse Company Secretary

Sun Biomedical Limited

Investor Communications

Computershare T: +61 1300 850 505 | F: +61 3 9473 2500

ASX:SBN

ABN 18 001 285 230

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/9/2001.

Name of entity	Sun Biomedical Limited
ABN	18 001 285 230

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Evan George Cross
Date of last notice	1 March 2012

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest(including registered holder)Note: Provide details of the circumstances giving rise tothe relevant interest.	a. Shares held in the name of Fullerton Private CapitalPty Ltd (Director and Shareholder); andb. Shares held in the name of Manhattan InvestmentsPty Ltd (Director and Shareholder).
Date of change	a. 14 December 2012; andb. 14 December 2012.
No. of securities held prior to change	a. 21,428,572 Shares (after 14:1 consolidation on2/10/2012); andb. 1,339,286 Shares (after 14:1 consolidation on2/10/2012).
Class	Shares
Number acquired	a. 8,000,000 Shares; andb. 1,339,286 Shares.
Number disposed	Nil
Value/Consideration includesbrokerage/gstNote: If consideration is non-cash, provide details andestimated valuation	a. $56,000.00; andb. $9,375.00.

• See chapter 19 for defined terms.

Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

No. of securities held after change

a. 29,428,572 Shares; and b. 2,678,572 Shares.

Nature of change	Take up under non-renounceable rights issue on
Example: on-market trade, off-market trade, exercise ofoptions, issue of securities under dividend reinvestment	14 December 2012
plan, participation in buy-back

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder(if issued securities)	N/A
Date of change	N/A
No. and class of securities towhich interest related prior tochangeNote: Details are only required for a contract in relationto which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/ConsiderationNote: If consideration is non-cash, provide details andan estimated valuation	N/A
Interest after change	N/A

Part 3 –[+] Closed period

Part 3 –+Closed period
Were the interests in the securities or contracts detailedabove traded during a+closed period where prior writtenclearance was required?	Issuedpursuanttononrenounceable rights issue
If so, was prior written clearance provided to allow the tradeto proceed during this period?	N/A
If prior written clearance was provided, on what date was thisprovided?	N/A

• See chapter 19 for defined terms.

Appendix 3Y Page 2